Effect of Recombinant Human Interleukin 2 on the Growth of a BALB/c Sarcoma Induced by Moloney Murine Sarcoma Virus

Overview

Journal Jpn J Cancer Res

Specialty Oncology

Date 1988 Aug 1

PMID 3141331

Citations 1

Authors

S Mitsunaga

H Kimura

Y Yamaguchi

A Mikata

Affiliations

Soon will be listed here.

Abstract

The effect of in vivo administration of recombinant interleukin 2 (rIL2) on the growth of a primary female BALB/c sarcoma induced by Moloney murine sarcoma virus (M-MSV) was studied. Although low-dose administration of (6,000 JU/mouse x 14 days) rIL2 had no effect on the growth of the tumors, high-dose (15,000-80,000 JU/mouse x 14 days) intraperitoneal inoculation of rIL2 induced tumor regression, dose-dependently. Tumors in mice which received 80,000 JU/mouse/day of rIL2 regressed completely 2 weeks after the initiation of treatment. The survival rates of the treated groups were significantly higher than those of the control group. A time course experiment disclosed that the effect of rIL2 was restricted only to the group in which rIL2 treatment started 8 days after the inoculation of M-MSV. The cytotoxic activity of regional lymph node lymphocytes from rIL2-treated mice was demonstrated against primary culture of M-MSV-induced sarcoma but not against syngeneic tumor induced by methylcholanthrene (Meth A). The effect of rIL2 was partially blocked by the administration of anti-IL2 receptor antibody. Immunohistochemical examination revealed that infiltration of Thy1.2+Lyt1+2- (helper/inducer subset) lymphocytes into the tumor tissue was prominent in mice which received high-dose rIL2. The results indicated that IL2 induced regression of M-MSV-induced sarcoma mainly through activation of IL2-receptor-positive helper T cells in the tumor tissues and of killer cells in the draining lymph nodes.

Citing Articles

Treatment of chemically induced autochthonous rat mammary and colorectal carcinomas with interleukin-2.

Berger M, Salas M, Garzon F, Petru E, Schwulera U, Schmahl D Cancer Immunol Immunother. 1991; 33(5):346-9.

PMID: 1868493 PMC: 11038629. DOI: 10.1007/BF01756601.

References

Lotze M, Frana L, Sharrow S, Robb R, Rosenberg S . In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol. 1985; 134(1):157-66. View

Maekawa R, Matsumoto M, Kitagawa T, Harada M, Sato K . Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563. Cancer Immunol Immunother. 1986; 23(1):25-30. PMC: 11038606. DOI: 10.1007/BF00205551. View

Knight R, Gorczynski R . Cell-mediated immunity to moloney sarcoma virus in mice. I. Analysis of antigens responsible for lymphocyte stimulation in regressor mice. Int J Cancer. 1975; 15(1):48-58. DOI: 10.1002/ijc.2910150107. View

Mule J, Shu S, Rosenberg S . The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol. 1985; 135(1):646-52. View

Rosenberg S, Grimm E, McGrogan M, Doyle M, Kawasaki E, Koths K . Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science. 1984; 223(4643):1412-4. DOI: 10.1126/science.6367046. View

Gillis S, Smith K . Long term culture of tumour-specific cytotoxic T cells. Nature. 1977; 268(5616):154-6. DOI: 10.1038/268154a0. View

Rosenberg S, Mule J, Spiess P, Reichert C, Schwarz S . Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985; 161(5):1169-88. PMC: 2187617. DOI: 10.1084/jem.161.5.1169. View

Mule J, Shu S, Schwarz S, Rosenberg S . Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984; 225(4669):1487-9. DOI: 10.1126/science.6332379. View

Massicot J, WOODS W, Chirigos M . Cell line derived from a murine sarcoma virus (Moloney Pseudotype)-induced tumor: cultural, antigenic, and virological properties. Appl Microbiol. 1971; 22(6):1119-22. PMC: 376495. DOI: 10.1128/am.22.6.1119-1122.1971. View

10.

Lafreniere R, Rosenberg S . Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. 1985; 45(8):3735-41. View

11.

Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T . The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. J Immunol. 1984; 133(3):1671-6. View

12.

Rosenberg S . Adoptive immunotherapy of cancer: accomplishments and prospects. Cancer Treat Rep. 1984; 68(1):233-55. View

13.

Rosenstein M, Yron I, Kaufmann Y, Rosenberg S . Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res. 1984; 44(5):1946-53. View

14.

Plata F, Jongeneel C . Characterization to effector lymphocytes associated with immunity to murine sarcoma virus (MSV)-induced tumors. II. Repeated stimulation and proliferation in vitro of specific cytolytic T lymphocytes. J Immunol. 1977; 119(2):623-9. View

15.

Mills C, NORTH R . Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells. J Exp Med. 1983; 157(5):1448-60. PMC: 2187010. DOI: 10.1084/jem.157.5.1448. View

16.

Forni G, Giovarelli M, Santoni A . Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. J Immunol. 1985; 134(2):1305-11. View

17.

Greenberg P, Cheever M, Fefer A . Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med. 1981; 154(3):952-63. PMC: 2186470. DOI: 10.1084/jem.154.3.952. View

18.

Kimura H, Yamaguchi Y . Distribution of in vitro-stimulated immune lymphocytes in mice bearing Moloney murine sarcoma virus-induced primary tumor. Gan. 1981; 72(1):72-80. View

19.

Rayner A, Grimm E, Lotze M, Chu E, Rosenberg S . Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer. 1985; 55(6):1327-33. DOI: 10.1002/1097-0142(19850315)55:6<1327::aid-cncr2820550628>3.0.co;2-o. View

20.

Rayner A, Grimm E, Lotze M, Wilson D, Rosenberg S . Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J Natl Cancer Inst. 1985; 75(1):67-75. View